| Aug 14 |
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
|
| Aug 7 |
Neumora Therapeutics GAAP EPS of -$0.37 beats by $0.04
|
| Aug 6 |
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 8 |
Mizuho starts Neumora at outperform, bullish on lead drug's prospects
|
| Jul 1 |
10 clinical trials to watch in the second half of 2024
|
| Jun 20 |
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
|
| May 22 |
This Neumora Therapeutics Insider Increased Their Holding In The Last Year
|
